The RNA-binding protein FMR1 has a key role in the neurodevelopmental disorder fragile X syndrome, but the RNAs targeted by the protein were mostly unknown. An analysis reveals thousands of possible targets. See Article p.382
Notes
*This article and the paper under discussion1 were published online on 12 December 2012.
References
Ascano, M. Jr et al. Nature 492, 382–386 (2012).
Feng, Y. et al. Mol. Cell 1, 109–118 (1997).
Eberhart, D. E. & Warren, S. T. Somat. Cell Mol. Genet. 22, 435–441 (1996).
Vasudevan, S. & Steitz, J. A. Cell 128, 1105–1118 (2007).
Laggerbauer, B., Ostareck, D., Keidel, E. M., Ostareck-Lederer, A. & Fischer, U. Hum. Mol. Genet. 10, 329–338 (2001).
Bear, M. F., Huber, K. M. & Warren, S. T. Trends Neurosci. 27, 370–377 (2004).
Darnell, J. C. et al. Genes Dev. 19, 903–918 (2005).
Darnell, J. C. et al. Cell 146, 247–261 (2011).
Bassell, G. J. & Warren, S. T. Neuron 60, 201–214 (2008).
Hafner, M. et al. J. Vis. Exp. 41, e2034 (2010).
Jayaseelan, S., Doyle, F., Currenti, S. & Tenenbaum, S. A. Meth. Mol. Biol. 714, 407–422 (2011).
Keene, J. D., Komisarow, J. M. & Friedersdorf, M. B. Nature Protoc. 1, 302–307 (2006).
Tenenbaum, S. A., Lager, P. J., Carson, C. C. & Keene, J. D. Methods 26, 191–198 (2002).
Caudy, A. A., Myers, M., Hannon, G. J. & Hammond, S. M. Genes Dev. 16, 2491–2496 (2002).
Ishizuka, A., Siomi, M. C. & Siomi, H. Genes Dev. 16, 2497–2508 (2002).
Jin, P. et al. Nature Neurosci. 7, 113–117 (2004).
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Jayaseelan, S., Tenenbaum, S. Signalling pathways of fragile X syndrome. Nature 492, 359–360 (2012). https://doi.org/10.1038/nature11764
Published:
Issue Date:
DOI: https://doi.org/10.1038/nature11764
- Springer Nature Limited
This article is cited by
-
Co-regulation of mRNA translation by TDP-43 and Fragile X Syndrome protein FMRP
Acta Neuropathologica (2016)
-
Modeling Neurodevelopmental Disorders Using Human Pluripotent Stem Cells
Stem Cell Reviews and Reports (2014)